Replimune Group, Inc. disclosed Rule 10b5-1 trading arrangements entered into during the quarter ended September 30, 2026, covering 488,119 shares for Philip Astley-Sparke, 99,665 shares for Sushil Patel and 160,372 shares for Konstantinos Xynos.
REPL · Replimune Group, Inc.
The latest filing states the doubt was alleviated.
“As described in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, substantial doubt existed about the Company's ability to continue as a going concern. The conditions that raised substantial doubt have been subsequently alleviated, as the Company raised approximately $141.0 million in net proceeds from an equity offering in August 2026.”View the 10-Q filed Oct 28, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 50%
- Last earnings
- Oct 28, 2026
- Latest filing
- 10-Q · Oct 28
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Replimune reported no product revenue in the fiscal second quarter, as first commercial shipments occurred in early October. Net loss for the quarter was $57.1 million, and cash ended the quarter at $307.8 million. Over 15 institutions have written one or more Tudrakev prescriptions, and about 20 accounts have placed it on formulary.
Replimune Group announced FDA accelerated approval of TUDRIQEV with nivolumab for unresectable advanced cutaneous melanoma after anti-PD-1 progression, with commercial launch in early October 2026. Net loss narrowed to $57.1 million for the three months ended September 30, 2026, from $83.1 million a year earlier, partly reflecting an April 2026 restructuring. Cash and cash equivalents were $307.8 million as of September 30, 2026.
Replimune said TUDRIQEV became commercially available in the United States with nivolumab for advanced melanoma, with first delivered to patients on October 6th. Fiscal second quarter net loss was $57.1 million, compared with $83.1 million a year earlier.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY27 earnings call · Oct 28, 2026TL;DR. TUDRIQEV’s early launch showed more than 70% engagement with the initial 200 priority accounts, prescriptions from more than 15 institutions, broad payer coverage, and continued enrollment of IGNYTE-3 and REVEAL. Net loss improved year over year, cash and cash equivalents were $307.8 million with funding expected to last greater than 12 months, but fiscal Q2 recorded no product revenue, the company is not providing revenue guidance, and SG&A increased sequentially for launch investments.
- + The commercial team is nearly fully staffed and ready to execute the launch.
- − No product revenue was recorded in fiscal Q2 2027 because first commercial shipments occurred in early October.
- − The company is not providing revenue guidance, and revenue from a patient may be recognized over more than one quarter.
- − SG&A expense increased from the prior quarter because of commercial launch investments.
- − TUDRIQEV’s accelerated approval and continued commercialization may depend on confirming clinical benefit.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
REPL
this stock
Replimune Group, Inc.
|
$1.82B | +97.8% | — | — | 26.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 6, 2026
- This year
- 25
Replimune Group, Inc. disclosed Rule 10b5-1 trading arrangements entered into during the quarter ended September 30, 2026, covering 488,119 shares for Philip Astley-Sparke, 99,665 shares for Sushil Patel and 160,372 shares for Konstantinos Xynos.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| REPL | -12.5% | +60.4% | +121.3% | +9.2% | +97.8% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -7.1% | +66.7% | +126.9% | +14.5% | +92.9% |